The Jakarta Meeting That Could Reshape Indonesian Access to Chinese Medicine

On August 7, 2026, the head of Indonesia's Food and Drug Authority (BPOM), Taruna Ikrar, met China's ambassador to Indonesia, Wang Lutong, in Jakarta to rebuild a regulatory bridge that has been down for more than two years. The Memorandum of Understanding between BPOM and China's National Medical Products Administration (NMPA) expired in June 2024 — and neither side let it lapse quietly. By Monday, August 10, Ikrar was publicly laying out a renewal that goes far beyond the old text: medicines, vaccines, biological products, pharmaceutical raw materials, natural medicines, cosmetics, and digital regulatory technology. ANTARA News carried the full statement.

The numbers behind the meeting explain why it matters. China already supplies a significant share of Indonesia's pharmaceutical raw materials — active pharmaceutical ingredients (APIs) and excipients — plus finished pharmaceutical products, and it accounts for roughly 30 percent of Indonesia's natural medicine imports. When a regulator and its biggest supplier start aligning their rules, the practical effect lands on patients: faster recognition of approvals, smoother clinical trial collaboration, and a more predictable path for therapies like CAR-T that Indonesia does not yet manufacture itself.

The numbers that matter

30%of Indonesia's natural medicine imports come from China
June 2024When the previous BPOM-NMPA MoU expired
~22%of China's inbound medical travelers come from Southeast Asia — the largest regional group
$30K-$151KThe full dual-track price range for CAR-T in China today

Why Indonesia Is the Market Chinese Hospitals Care About Most

Indonesia is not a marginal patient source for Chinese hospitals — it is the core one. Southeast Asian patients, with Indonesians the largest national group, make up roughly one in five of the international patients treated in China, concentrated in oncology, cardiac care and orthopedics. The reasons are structural: Chinese centers offer CAR-T and advanced surgery at prices that undercut Singapore, Thailand, Korea and India, waitlists are short or nonexistent, and the flight from Jakarta to Shanghai is about six hours.

What the BPOM-NMPA renewal adds is a regulatory layer on top of that existing patient flow. When a patient's home regulator and the treating country's regulator are actively cooperating — sharing inspection standards, exploring mutual recognition — the trip stops feeling like a leap into the unknown and starts feeling like a routine referral. That is the psychological shift medical tourism depends on, and it is exactly what this MoU is designed to produce.

What the Renewed MoU Covers

Ikrar's statement names seven workstreams, each with a patient-facing consequence:

  • Medicines and vaccines — the core of the old pact, now with a stated goal of faster access through regulatory reliance.
  • Biological products — including biosimilars and advanced therapy medicinal products (ATMP), the regulatory category that covers CAR-T cell therapy.
  • Pharmaceutical raw materials — the API and excipient supply chain that China dominates.
  • Natural medicines — the category where China holds a 30 percent import share, and where traditional Chinese medicine (TCM) and Indonesian jamu meet.
  • Cosmetics and processed food safety — the consumer-facing end of the same quality-assurance framework.
  • Digital regulatory technology — data sharing, e-submissions and digital inspection tools that make cooperation faster than paper-based processes.
  • Clinical trial oversight and Good Clinical Practice (GCP) inspections — the piece that directly touches patients enrolled in cross-border trials.

Ambassador Wang responded with a concrete offer: Chinese investment in Indonesia's health sector, medical device technology transfer, and exploring the possibility of manufacturing facilities inside Indonesia. Regulatory cooperation, in other words, is the scaffolding for a much larger commercial relationship.

Regulatory Reliance: The Shortcut That Gets CAR-T to Indonesian Patients

The single most consequential phrase in the statement is "regulatory reliance and collaborative review." In plain language: Indonesia's BPOM would be able to lean on China's NMPA assessment when deciding whether a product is safe and effective — instead of re-running the entire review from zero.

For cell therapy, this matters enormously. CAR-T is the flagship of China's solid tumor and hematology programs: the NMPA has approved multiple CAR-T products, including satri-cel (Claudin18.2, gastric cancer, the world's first solid-tumor CAR-T approval) and the domestic relmacabtagene (Carteyva), while a pipeline of in vivo CAR-T candidates moves through trials. Indonesia has no approved CAR-T product of its own. Every Indonesian patient who needs one currently travels — most often to China.

The price picture is the reason they keep coming. The verified dual-track range for CAR-T in China: commercial NMPA-approved products at $89,000-$151,000, and clinical trial or charity access at $30,000-$80,000 — against $300,000-$500,000 for the same class of therapy in the United States. Satri-cel itself runs $89,000-$170,000 depending on the hospital and package. A regulatory framework that recognizes Chinese approval data does not change those prices, but it does change the long-term picture: if Indonesian hospitals ever begin offering these products locally under a reliance pathway, the travel burden for follow-up care shrinks. That is a 3-5 year horizon, not a 3-5 month one — the MoU is the first step, not the finish line.

Honest calibration: the MoU renewal is a framework, not a fast-track guarantee. It was still being negotiated as of August 10, 2026, and the previous version took years to expire without a replacement. Nothing in this article should be read as "CAR-T is now approved in Indonesia." The realistic reading is that both regulators now have a shared, written agenda — and the agenda explicitly includes ATMP, natural medicines and clinical trials.

The Traditional Medicine Thread: China's 30 Percent Share

Indonesia is a country with its own deep herbal tradition — jamu — and it imports a third of its natural medicines from China. That makes the natural-medicines workstream of the MoU a meeting point of two herbal systems, not a one-way street.

For Chinese hospitals treating international patients, the TCM dimension of the pact matters because it legitimizes what those hospitals already do. International patients at Chinese oncology centers commonly receive integrated TCM-western supportive care alongside chemotherapy — herbal formulas for nausea, acupuncture for pain, moxibustion and tuina in rehabilitation — and China's five-year TCM plan through 2030 is explicitly built around making that integration exportable. A regulatory agreement that sets quality standards for natural medicines in both markets gives Indonesian patients a compliant, documented answer to the question every family asks: "is this herbal medicine safe?" When BPOM and NMPA are inspecting to shared standards, the answer comes with paperwork instead of promises.

ANTARA's related coverage notes that Indonesia has also been exploring a traditional medicine center partnership with China — a project that, if it proceeds, would give the herbal thread of this relationship a physical home. Nothing has been signed; the exploration itself is the news.

Clinical Trials: The Fastest Legal Route Is About to Get More Credible

For Indonesian patients with advanced cancer, the fastest route to a novel therapy is often a Chinese clinical trial — CAR-T trials in particular enroll international patients at major centers, and the cost of trial participation sits at the bottom of the dual-track range ($30,000-$80,000 all-in). The GCP-inspection workstream of the MoU speaks directly to that route: when the patient's home regulator inspects and recognizes the same trial standards, the trial participation carries an official stamp of credibility that helps with insurance claims, employer documentation and family trust.

What an Indonesian Patient Should Do Today

The MoU will take months to finalize. The patient path to China does not need to wait for it:

  1. Choose the hospital by disease. For hematologic CAR-T (lymphoma, leukemia, myeloma), Ruijin Hospital in Shanghai runs one of China's strongest hematology programs, with direct daily flights from Jakarta. For satri-cel and solid tumors, Jiahui International Hospital (Shanghai) and Peking University Cancer Hospital (Beijing) are commercial launch sites with international-standard care — a full hospital guide is here.
  2. Plan the visa. Indonesian citizens get 30-day visa-free entry for tourism or business, but a 4-6 week CAR-T stay needs the M (medical) visa, which requires a hospital invitation letter — typically issued within 5-7 working days.
  3. Confirm language and logistics. The international departments at Jiahui, Ruijin and Peking University Cancer Hospital arrange Bahasa Indonesia translators with 5-7 days' notice, and halal meals are available at all three.
  4. Ask for the dual-track price in writing. Request both the commercial quotation and any trial-access option, so the $30K-$80K versus $89K-$151K decision is made on paper, not in conversation.
  5. Bring your Indonesian records. Under the planned GCP cooperation, trial sponsors and hospitals expect documented prior-treatment history; translated medical records shorten the review from weeks to days.

The Bottom Line

The BPOM-NMPA renewal is the most concrete regulatory signal yet that China and Southeast Asia's largest economy intend to move as one medical market. For the Indonesian patient — the single biggest national group in China's inbound medical tourism — it means a more credible path to CAR-T therapy, a documented route for traditional Chinese medicine within a familiar herbal tradition, and a clinical trial system that her own regulator is helping to supervise. The pact is not yet signed. The direction, after August 7, is unmistakable.

Frequently Asked Questions

What is the BPOM-NMPA MoU and why is it being renewed? The Memorandum of Understanding between Indonesia's BPOM and China's NMPA expired in June 2024. On August 7, 2026, BPOM head Taruna Ikrar met China's ambassador in Jakarta to renew it with a broader scope covering medicines, vaccines, biological products, pharmaceutical raw materials, natural medicines, cosmetics and digital regulatory technology. The renewal is expected to be finalized through the diplomatic channel.

How does the BPOM-NMPA pact affect Indonesian patients seeking CAR-T in China? The pact promotes regulatory reliance and collaborative review, which could let Indonesian authorities recognize Chinese clinical and approval data for advanced therapy medicinal products (ATMP) such as CAR-T. Today, Indonesian patients already travel to China for CAR-T — commercial NMPA-approved products cost roughly $89,000-$151,000, with trial access from $30,000-$80,000 — and smoother regulatory alignment would make that path more predictable over time.

What does the pact mean for traditional Chinese medicine (TCM) products? China accounts for around 30 percent of Indonesia's natural medicine imports. The renewed MoU explicitly covers natural medicines, and BPOM has separately been exploring a traditional medicine center partnership with China. Tighter safety and quality cooperation is intended to keep herbal products compliant in both markets rather than to restrict them.

Can Indonesian patients join clinical trials in China under this cooperation? Clinical trial oversight and Good Clinical Practice (GCP) inspections are part of the planned cooperation, which supports cross-border trial participation. Indonesian patients can already join Chinese trials directly through hospital international departments, and regulators cooperating on GCP standards makes the trial route more credible for both sides.

Related Reading